Clinical Trial: A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)

U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07791043) titled 'A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)' on Aug. 21.

Brief Summary: This is a dose-ranging study to evaluate safety of efimosfermin alfa and to establish proof-of-concept that efimosfermin alfa therapy provides benefit in participants with ALD.

Study Start Date: Sept. 23

Study Type: INTERVENTIONAL

Condition: Liver Diseases, Alcoholic

Intervention: DRUG: Efimosfermin alfa

Efimosfermin alfa will be administered.

DRUG: Placebo

Placebo will be administered.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: GlaxoSmith...